Genmab — September 2024
-
-
the company can breathe a bit easier thanks to the assumption that Darzalex Faspro, the Halozyme-partnered subcutaneous version of J&J’s multiple myeloma blockbuster, will be safe from price negotiations for the foreseeable future thanks to its under-the-skin formulation, Taubert said
-
-
Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies https://onlinelibrary.wiley.com/doi/10.1111/imr.13394?af=R [The review will summarize the development, preclinical, and clinical testing of several HexaBodies designed for the treatment of B-cell malignancies, as well as the potential use of the HexaBody technology beyond Fc-mediated effector functions.]
-
not sure anyone saw this yet for congress presentations
https://www.genmabmedicalaffairs.com/congress -
for example Rinatabart Sesutecan
(Rina-S) at ESMO https://www.genmabmedicalaffairs.com/sfsites/c/sfc/servlet.shepherd/document/download/069Po00000IYCh9IAH
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind